Ten Years of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Evolution of Classification and Correlation with Follow-up in 50 Patients

被引：0
|
作者：
Grillo, F. [1 ]
Albertelli, M. [1 ]
Giannone, A. [1 ]
Mastracci, L. [1 ]
Annunziata, F. [1 ]
Arvigo, M. [1 ]
Minuto, F. [1 ]
Fiocca, R. [1 ]
Ferone, D. [1 ]
机构：
[1] Univ Genoa, Genoa, Italy
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
neuroendocrine; grade; prognosis;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [31] The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Saif, Wasif M.
    Parikh, Rohan
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh P.
    Soares, Heloisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Gene expression characterization of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and their correlation with clinical factors and tumor behavior: initial molecular profile
    Fonseca, P. J.
    Diaz Perez, J. A.
    Crespo Herrero, G.
    Villabona, C.
    Blanco, C.
    Gonzalez Garcia, C.
    Garcia-Carbonero, R.
    Luque, R.
    Castano, J.
    Martinez Fuentes, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S637 - S637
  • [33] Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) of Unknown Primary: A Diagnostic Strategy for Localizing the Primary Lesion
    Mann, Neel K.
    Basseri, Robert J.
    Jamil, Laith H.
    Nissen, Nicholas N.
    Colquhoun, Steven D.
    Wolin, Edward M.
    Lo, Simon K.
    GASTROENTEROLOGY, 2011, 140 (05) : S88 - S88
  • [34] The Sequencing of Lanreotide (LAN) After Octreotide LAR (OCT) for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Saif, Wasif M.
    Parikh, Rohan C.
    Ray, David
    Kaye, James A.
    Kurosky, Samantha K.
    Thomas, Katharine
    Halfdanarson, Thorvardur R.
    Beveridge, Thomas
    Mirakhur, Beloo
    Lubeck, Catherine A.
    Nagar, Saurabh
    Soares, Heloisa
    PANCREAS, 2019, 48 (03) : 450 - 450
  • [35] Y90-DOTATATE in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Survival following Different Indications for Treatment
    Khan, M. S.
    El-Khouly, F.
    Quigley, A. M.
    Caplin, M.
    Toumpanakis, C.
    NEUROENDOCRINOLOGY, 2011, 94 : 31 - 31
  • [36] Clinical epidemiology study of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A 10-year retrospective study in China
    Yan, H.
    Jiang, L.
    Yang, H.
    Chi, Y.
    Fan, J.
    Qiao, Y.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 83 - 83
  • [37] pmTOR and vascular endothelial growth factor receptor (VEGFR)-2 expressions in gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Kim, Hee Sung
    Lee, Hye Seung
    Kim, Woo Ho
    CANCER RESEARCH, 2012, 72
  • [38] A RETROSPECTIVE REAL-WORLD EVIDENCE STUDY OF PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) IN THE US USING THE OPTUM DATABASE
    Kunz, P.
    Honeycutt, H.
    Ward, P.
    Dasari, A.
    VALUE IN HEALTH, 2021, 24 : S64 - S64
  • [39] Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Phan, Alexandria T.
    Dasari, Arvind
    Liyanage, Nilani
    Cox, David
    Lowenthal, Susan Pitman
    Wolin, Edward M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [40] Phase II Study of Sunitinib Following Hepatic Artery Embolization for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Strosberg, Jonathan
    Campos, Tiffany
    Kvols, Larry
    PANCREAS, 2010, 39 (02) : 280 - 281
12345